Navigation Links
Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients With PROVENGE
Date:10/27/2010

MARINA DEL REY, Calif., Oct. 27 /PRNewswire/ -- Prostate Oncology Specialists, Inc. of Marina del Rey is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.  PROVENGE was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and is made by Dendreon Corporation.

(Photo:  http://photos.prnewswire.com/prnh/20101027/SF89964)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20101027/SF89964)

"PROVENGE is a scientific breakthrough that paves the way for similar personalized treatments in other cancer types," said Dr. Mark Scholz, Medical Director of Prostate Oncology Specialists and co-founder of the Prostate Cancer Research Institute. "I'm pleased to have a new option to present to my patients and to be a part of the first physician-based facility in the area treating patients with this important new FDA approved therapy."

Prostate Oncology Specialists have treated over 30 patients with PROVENGE to date, and anticipates providing the therapy to many more men with metastatic castrate resistant prostate cancer as supply of the drug increases over the next six months.

"I was excited about using PROVENGE because it allowed me to use my own cells to help fight cancer," said PROVENGE patient Frank La Barba of Long Beach, CA. "My side-effects were mild and following my treatment, I was able to get back to doing the activities I did before receiving therapy, such as traveling and photography."

PROVENGE is an autologous (made from a patient's own immune cells) cellular immunotherapy designed to stimulate a patient's immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his immune cells.

The Centers for Medicare and Medicaid Services are currently undergoing a National Coverage Analysis (NCA) regarding autologous cellular immunotherapy treatment of metastatic prostate cancer.  As part of the NCA process, Dr. Scholz will provide an expert opinion on PROVENGE data at the November 17th Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting in Baltimore, MD.

In addition, Dr. Scholz will be giving a presentation on the latest developments in treating advanced prostate cancer, including new immunological approaches such as PROVENGE and effective chemotherapy combinations, at an UsTOO educational session in Fullerton, CA on Thursday, October 28th beginning at 5 p.m. PT.  For press attendance credentials or information on location for patients, please contact Lew Pfeffer at (626) 333-6034.

PROVENGE Safety

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the PROVENGE group included acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events.  Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group.  Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

The most common adverse events (incidence >15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see full Prescribing Information for PROVENGE at www.provenge.com.

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 217,730 new cases and approximately 32,050 men expected to die from the disease in 2010.

Individuals interested in learning whether PROVENGE is an appropriate treatment option should contact Jennifer Leung at (310) 827-7707, extension 32 or Dendreon On-Call at (877) 336-3736.  For full Prescribing Information, please visit www.PROVENGE.com.

About Prostate Oncology Specialists, Inc.

Established in 1995, Prostate Oncology Specialists has earned national acclaim for its comprehensive approach to prostate cancer prevention and management. Under the direction of Medical Director, Mark Scholz, M.D., Prostate Oncology Specialists employs a highly-skilled team of physicians trained in oncology, hematology and internal medicine. Prostate Oncology Specialists are not wedded to any single therapy for prostate cancer, but rather advocate the exploration of treatment options that are customized and tailored to the unique needs of each individual patient. Prostate Oncology Specialists' ongoing mission is to uncover new medical breakthroughs in the treatment and management of prostate cancer.

About Prostate Cancer Research Institute

PCRI is a 501(c)(3) not-for-profit education and research organization founded in 1996 by Mark Scholz, M.D. and Stephen Strum, M.D.. The PCRI educates patients and their families about prostate cancer. This includes new advances in diagnosis, staging, treatments and available resources. PCRI believes that a patient who understands his disease and treatment is empowered to communicate more effectively with his physicians and obtain a better outcome. PCRI intends to use all available communication tools to accomplish this most important objective.

RELATED LINKS

provenge.com

prostateoncology.com

pcri.org


'/>"/>
SOURCE Prostate Oncology Specialists, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Prostate Cancer Drug Futures
2. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone
3. Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
4. Prostate Cancer Treatment Expert Dr. David Samadi, MD Discusses Study Which Found That Low-Income Men Had High-Risk Prostate Cancer Tumors
5. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
6. Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnsons Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
7. AMS Announces Worldwide Launch of the Revolutionary MoXy™ Liquid Cooled Fiber for Fast, Safe Treatment of Enlarged Prostate
8. With Over 3,000 Robotic Prostatectomy Surgeries to His Credit, Dr. David Samadi, MD Discusses SMART Surgery and How it Improves Sexual and Urinary Function
9. Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer
10. Robotic Prostatectomy Expert Dr. David Samadi, MD Introduces His SMART Surgery Website for Prostate Cancer Treatment Education
11. ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):